INBX Inhibrx, Inc. Stock Quote

INBX [NASD]

Index	-	P/E	-	EPS (ttm)	-2.86	Insider Own	31.57%	Shs Outstand	39.04M	Perf Week	-15.74%
Market Cap	608.82M	Forward P/E	-	EPS next Y	-3.81	Insider Trans	-0.93%	Shs Float	26.73M	Perf Month	-39.18%
Income	-110.80M	PEG	-	EPS next Q	-0.94	Inst Own	68.80%	Short Float	12.20%	Perf Quarter	28.77%
Sales	7.00M	P/S	86.97	EPS this Y	-6.60%	Inst Trans	7.74%	Short Ratio	7.48	Perf Half Y	-24.84%
Book/sh	-0.13	P/B	-	EPS next Y	-10.70%	ROA	-69.90%	Target Price	46.17	Perf Year	-53.84%
Cash/sh	4.36	P/C	3.45	EPS next 5Y	-	ROE	-430.10%	52W Range	7.67 - 47.90	Perf YTD	-65.56%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-62.30%	52W High	-69.29%	Beta	-
Dividend %	-	Quick Ratio	7.50	Sales past 5Y	-	Gross Margin	-	52W Low	91.79%	ATR	1.82
Employees	106	Current Ratio	7.50	Sales Q/Q	-30.00%	Oper. Margin	-	RSI (14)	33.91	Volatility	7.96% 9.19%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	-76.50%	Profit Margin	-	Rel Volume	0.64	Prev Close	15.04
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	436.16K	Price	14.71
Recom	1.80	SMA20	-26.34%	SMA50	-20.81%	SMA200	-35.84%	Volume	53,398	Change	-2.19%

Mar-16-22

Initiated

SMBC Nikko

Outperform

$40

Sep-21-21

Initiated

JMP Securities

Mkt Outperform

$46

Apr-26-21

Resumed

Credit Suisse

Outperform

$44

Sep-14-20

Initiated

Evercore ISI

Outperform

$30

Sep-14-20

Initiated

Credit Suisse

Outperform

$26

Aug-15-22 04:05PM	European Medicines Agency Grants Orphan Drug Designation to INBRX-109 for the Treatment of Chondrosarcoma PR Newswire
Aug-08-22 07:25PM	Inhibrx, Inc. (INBX) Reports Q2 Loss, Lags Revenue Estimates Zacks +8.27%
05:19PM	Inhibrx Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights PR Newswire
Jun-30-22 09:00AM	Inhibrx Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105, a Novel Targeted 4-1BB Agonist, and Draws an Additional $60 Million from Oxford Finance PR Newswire -5.34%
May-19-22 04:05PM	Inhibrx Announces Details of Presentation at 2022 ASCO Annual Meeting PR Newswire -5.08%
May-16-22 12:32PM	Inhibrx's INBRX-101 Shows Favorable Safety Profile In An Inherited Disorder Benzinga -18.95%
09:00AM	INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates Potential to Achieve Normal Functional Alpha-1 Antitrypsin Levels with Monthly Dosing PR Newswire
May-09-22 06:35PM	Inhibrx, Inc. (INBX) Reports Q1 Loss, Misses Revenue Estimates Zacks -6.23%
05:25PM	Cara Therapeutics (CARA) Reports Q1 Loss, Lags Revenue Estimates Zacks
04:05PM	Inhibrx Reports First Quarter 2022 Financial Results and Recent Corporate Highlights PR Newswire
May-05-22 05:15PM	KaloBios Pharmaceuticals Inc. (HGEN) Reports Q1 Loss, Misses Revenue Estimates Zacks -7.76%
06:18AM	The 17% return this week takes Inhibrx's (NASDAQ:INBX) shareholders one-year gains to 25% Simply Wall St.
May-03-22 06:32AM	Inhibrx, Inc. (INBX) Soars 15%: Is Further Upside Left in the Stock? Zacks
Apr-25-22 09:00AM	Inhibrx Announces Formation of Scientific Advisory Board for INBRX-101 PR Newswire
Apr-05-22 04:30PM	Inhibrx to Present INBRX-101 Data at ATS 2022 Annual Meeting PR Newswire -5.50%
Mar-24-22 04:05PM	Inhibrx Announces Details of Presentations at 2022 AACR Annual Meeting PR Newswire
Mar-03-22 09:15AM	Inhibrx Receives FDA Orphan-Drug Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency PR Newswire
Feb-28-22 04:05PM	Inhibrx Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Recent Corporate Highlights PR Newswire
Feb-22-22 09:00AM	Inhibrx Announces Amended Loan Agreement with Oxford PR Newswire
Jan-05-22 07:46AM	Inhibrx Shares Interim Data On INBRX-106 - Keytruda Combo Therapy In Solid Tumors Benzinga -5.83%
Jan-04-22 04:05PM	Inhibrx Announces Initial Phase 1 Dose Escalation Results for INBRX-106, a Novel Hexavalent OX40 Agonist, in Combination with Keytruda® (Pembrolizumab) Along with Updated Single Agent Data PR Newswire -8.62%
Dec-20-21 08:50AM	Here's What Could Help Inhibrx, Inc. (INBX) Maintain Its Recent Price Strength Zacks
Dec-01-21 04:05PM	Inhibrx Receives FDA Orphan-Drug Designation for INBRX-109 in Chondrosarcoma PR Newswire
Nov-25-21 09:08AM	Takeda (TAK) CMV Infection Drug Livtencity Gets FDA Approval Zacks
Nov-24-21 10:31AM	Amryt (AMYT) Skin Disorder NDA Review Gets 3 Months Extension Zacks +5.48%
Nov-23-21 10:00AM	Wall Street Analysts Predict a 32% Upside in Inhibrx, Inc. (INBX): Here's What You Should Know Zacks
Nov-10-21 07:47AM	Inhibrx (NASDAQ:INBX) pulls back 3.4% this week, but still delivers shareholders impressive 139% return over 1 year Simply Wall St.
Nov-09-21 06:45PM	Inhibrx, Inc. (INBX) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:05PM	Inhibrx Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights PR Newswire
Nov-05-21 03:00PM	Inhibrx, Inc. (INBX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Zacks
Nov-03-21 08:00AM	Inhibrx Announces Presentations at SITC 2021 PR Newswire
Nov-01-21 05:51PM	Inhibrx Announces Participation in Upcoming Scientific and Investor Conferences PR Newswire +14.51%
Oct-28-21 08:30AM	Inhibrx Strengthens Leadership Team with Three Key Executive Hires and Announces Appointment of Kristiina Vuori, M.D., Ph.D. to its Board of Directors PR Newswire
Oct-12-21 12:22PM	30 Stocks Moving In Tuesday's Mid-Day Session Benzinga +21.98%
12:11PM	Here's Why Inhibrx Stock Is on the Move Today Motley Fool
07:30AM	INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates the Potential to Achieve Normal Alpha-1 Antitrypsin Levels with Monthly Dosing PR Newswire
Oct-11-21 04:05PM	Inhibrx To Host Webcast Presentation of Interim Results from the Phase 1 Trial of INBRX-101, its Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency PR Newswire
Sep-13-21 04:30PM	Inhibrx Announces Participation in Upcoming Investor Conference PR Newswire
Aug-12-21 01:37AM	The Inhibrx, Inc. (NASDAQ:INBX) Second-Quarter Results Are Out And Analysts Have Published New Forecasts Simply Wall St. -6.10%
Aug-09-21 04:38PM	Inhibrx Reports Second Quarter 2021 Financial Results PR Newswire
Jun-22-21 06:49AM	Inhibrx Launches Mid-Stage Bone Cancer Study With INBRX-109, Amends Loan Agreement With Oxford Benzinga
Jun-21-21 04:05PM	Inhibrx Initiates a Potential Registration-Enabling Phase 2 Study of INBRX-109 in Conventional Chondrosarcoma Patients, Updates Data for Ongoing Phase 1 Study and Announces Amended Loan Agreement with Oxford PR Newswire
May-17-21 04:05PM	Inhibrx Announces Participation in Upcoming Investor Conferences PR Newswire
May-13-21 04:10PM	Inhibrx Reports First Quarter 2021 Financial Results PR Newswire
Mar-14-21 03:21AM	Inhibrx Surpasses 4Q Revenue Estimates; Street Remains Bullish SmarterAnalyst
Mar-12-21 09:00AM	Inhibrx Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Announces Phase 1 Single Agent Dose Escalation Results for INBRX-105, a Novel Targeted 4-1BB Agonist PR Newswire -6.37%
Feb-01-21 05:42PM	Inhibrx Announces Participation in Upcoming Investor Conference PR Newswire +7.32%
Jan-13-21 09:00AM	Inhibrx Granted Fast Track Designation for INBRX-109 for the Treatment of Unresectable or Metastatic Conventional Chondrosarcoma Patients PR Newswire +13.16%
Dec-10-20 06:24PM	Is INBX A Good Stock To Buy Now? Insider Monkey +9.32%
Nov-13-20 04:10PM	Inhibrx Reports Financial Results for the Third Quarter 2020 and Announces Amended Loan Agreement with Oxford PR Newswire
Nov-11-20 04:05PM	Inhibrx Announces Positive Interim Results from the Phase 1 Trial of INBRX-109 in Chondrosarcoma Patients PR Newswire
Nov-05-20 04:05PM	Inhibrx Announces Participation in Upcoming Investor and Scientific Conferences PR Newswire
Aug-25-20 12:17PM	Oxford Finance Announces $10 Million Credit Facility with Inhibrx, Inc. PR Newswire
Aug-21-20 04:00PM	Inhibrx Announces Closing of Initial Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Eckelman Brendan P.	Chief Scientific Officer	Sep 06	Sale	14.91	40,000	596,274	2,435,553	Sep 07 04:57 PM
Eckelman Brendan P.	Chief Scientific Officer	Aug 03	Sale	18.47	15,500	286,209	2,475,553	Aug 04 04:33 PM
Eckelman Brendan P.	Chief Scientific Officer	Aug 02	Sale	17.70	24,500	433,626	2,491,053	Aug 04 04:33 PM
Eckelman Brendan P.	Chief Scientific Officer	Jul 07	Sale	17.17	40,000	686,800	2,515,553	Jul 08 04:03 PM
Eckelman Brendan P.	Chief Scientific Officer	Apr 05	Sale	25.04	400	10,016	2,555,553	Apr 07 04:11 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience